Reducing the impact of cancer through genetic diagnosis: new technological challenges New diagnostic strategy published in two papers in Scientific Reports
A new strategy to improve genetic diagnosis for families with hereditary cancer Read More »
Hotel Barcelona Princess entrega cheque simbólico de 16.000 € de las donaciones recaudadas al CIBERER Hotel Barcelona Princess lucha contra las enfermedades raras reto solidario 16.000 € CIBERER
El Hotel Barcelona Princess entrega 16.000€ a la investigación de las enfermedades raras Read More »
Researchers from the Genes and Cancer research group at the Bellvitge Biomedical Research Institute (IDIBELL) have identified inactivating mutations in a number of genes that code for HLA-I histocompatibility complex proteins, which are involved in the immune response and can condition the tesponse of lung cancer patients to immunotherapy. The study is a result of
In its 7th edition, the sports test will collect voluntary donations for the investigation of children’s sarcoma that is carried out in the IDIBELL Tear down the wall Run with a 100% charitable race numbers!
SB Hotels Tarragona Marathon wants to tear down the wall of childhood cancer Read More »
Researchers at the Center for Computer Vision and Bellvitge Hospital – IDIBELL have developed a technology that allows physicians to locate and move around the patients’ bronchi following a planned and localized route thanks to augmented reality techniques, video games and 3D modeling. The objective of this collaboration is to improve the existing technology in
A bronchial GPS based on digital imaging for the early detection of lung cancer Read More »
appointment of Dr. Gabriel Capellá as director of IDIBELL.
Gabriel Capellá, director of IDIBELL Read More »
Researchers from the proCURE ICO-IDIBELL breast cancer research group have first described why tumors adapt to and resist therapy with mTOR inhibitors, a treatment used in advanced stages of this cancer. The results of this international study, published in the journal Oncogene, sets new steps towards a more personalized selection of cancer therapies. The mTOR
Researchers of the TGF-beta and Cancer group of Bellvitge Biomedical Research Institute (IDIBELL), in collaboration with King’s College London, have unveiled the role of NADPH oxidase NOX4 as an inhibitor of the epithelial-amoeboid transition, a process that contributes to the migration and invasion of tumor cells. The study has just been published in the journal
Researchers identify new suppressor effects of the NOX4 protein in liver cancer Read More »
The City Council and the research center join forces to raise funds against intellectual disability 100 years Sinatra
L’Hospitalet Christmas Concerts raise funds for IDIBELL Read More »
Removal of antibodies with glycoconjugates Valuation and commercialisation, pending challenges
CaixaImpulse funds an IDIBELL project on hospital-acquired infections Read More »
